ArticleScientific reports2025
Protective effects of metabolites from lactic acid bacteria against infections of mastitis pathogen in bovine cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Probiotics as Sustainable Alternatives to Mitigate Antibiotic Resistance in Bovine Mastitis Management.Probiotics and antimicrobial proteins · 2026Review
- Postbiotics combined with Caesalpinia sappan L. extract inhibit bovine mastitis bacterial pathogens, promote anti-inflammation and in vitro wound healing property.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bovine mastitis poses significant economic challenges for dairy farms globally. Metabolites from lactic acid bacteria (LAB) offer promising alternative substances for preventing bovine mastitis. This study demonstrated the inhibitory activity of metabolite production from seven LAB isolates in the supernatant medium. Four isolates, namely Lactiplantibacillus plantarum TISTR 2070, Lacticaseibacillus casei TISTR 1340, Enterococcus faecalis TCAN02, and Lactiplantibacillus plantarum AD73, exhibited antibacterial activity against bacterial pathogens causing mastitis, including Staphylococcus haemolyticus, Staphylococcus capitis subsp. ureolyticus, Streptococcus agalactiae O4, Streptococcus dysgalactiae, and Streptococcus uberis. The minimum inhibitory concentration (MIC) values ranged from 6.25 to 25 mg/mL, with minimum bactericidal concentration (MBC) values of 12.5 to 25 mg/mL. Furthermore, analysis of the physical and chemical properties revealed active metabolites in LAB supernatants, particularly lactic acid that was detected in all samples. Additionally, this study presents novel findings on infection of CPAE bovine endothelial cells in vitro by mastitis bacterial pathogens and demonstrating cytopathic effects such as vacuolation, magalocytosis, and cytotoxicity after bacterial infection on the bovine endothelial cells. Moreover, metabolites from LAB supernatant exhibited a protective effect against bacterial colonization and infection of bacterial pathogens causing mastitis on CPAE bovine endothelial cells and leading to increase cell viability. The results of this study suggest that metabolites from LAB samples exert potential candidates as alternative therapeutic agents for bovine mastitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.